What AACE 2025 Revealed About the Future of Inpatient Glycemic Control

The 2025 AACE Annual Meeting brought together some of the brightest minds in endocrine care and the message was clear: glycemic control is no longer a background concern in hospitals.

It’s becoming a central performance metric for hospitals, with real implications for patient safety, clinical outcomes, and financial health.

Hospitals Are Not Prepared for What’s Coming in 2026

One of the most important takeaways came from Dr. Misha Zilbermint of Johns Hopkins, who reminded us that Centers for Medicare & Medicaid Services (CMS) will begin requiring hospitals to report rates of inpatient hypo- and hyperglycemia next year.

Noncompliance could result in penalties, but what’s more concerning is how many hospitals are still not monitoring this data.

Dr. Zilbermint highlighted that clinical decision support systems like EndoTool® can make this tracking seamless, providing real-time insight down to the unit level and helping teams drive glycemic control improvement before they’re penalized. Now is the perfect time for hospitals to take action and position themselves for success.

Managing New Risks: Euglycemic DKA on the Rise

As newer therapies like SGLT2 inhibitors and GLP-1 receptor agonists gain ground, we’re seeing shifts in the types of glycemic emergencies presenting in the hospital.

Dr. Rifka Schulman-Rosenbaum gave a timely talk on euglycemic DKA, which is easy to miss, and dangerous when overlooked.

This is especially relevant at Monarch, as EndoTool IV now offers an FDA-cleared dosing mode which may be used in the treatment of hyperglycemic crises like euglycemic DKA.

It is a reflection of where inpatient medicine is going- toward more nuanced decision support that can adapt to complex patient needs.

Real-World Proof: DKA Outcomes with EndoTool

One of the highlights of the meeting for me was presenting our poster on Improved Mortality, Length of Stay, and Cost of Care in DKA with Dr. Greg Deines. We shared Corewell Health West’s DKA results using EndoTool.

In short:

• $1,200 saved per admission
• Lower mortality than expected
• Significant reduction by over 50% in ICU length of stay

These aren’t incremental gains – they’re transformative. And they show what’s possible when hospitals invest in precise, patient-specific insulin dosing.

The Shift Is Happening – Is Your Hospital Ready?

The sessions at AACE painted a clear picture: glycemic control is no longer just a clinical goal, it’s a system-level priority.

Whether it’s improving perioperative protocols for patients on newer diabetes agents or preparing for CMS reporting requirements, hospitals need clinical decision support that is efficient, adaptable, and grounded in clinical safety.

EndoTool has long supported hospitals in achieving tighter control with lower risk and we’re continuing to evolve to meet the demands of modern inpatient care.

We look forward to bringing even more data and innovations to AACE 2026 in Las Vegas. Until then, we remain focused on empowering hospitals to deliver better glycemic care through patient-specific insulin dosing.

About EndoTool

Made by Monarch Medical Technologies, EndoTool is the only patient-specific insulin dosing system which simplifies the complex task of glycemic management in hospital environments. The recommended dosing is different for each patient based on multiple clinical characteristics. The FDA-cleared platform is utilized in hundreds of hospitals across the United States and is fully integrated with all major electronic medical records. To see how EndoTool can support your health system, get in touch today.